Literature DB >> 17420908

Intestinal permeability and malabsorption of rifampin and isoniazid in active pulmonary tuberculosis.

Valéria G F Pinheiro1, Lysiane M A Ramos, Helena S A Monteiro, Elizabeth C Barroso, Oluma Y Bushen, Mônica C Façanha, Charles A Peloquin, Richard L Guerrant, Aldo A M Lima.   

Abstract

Low antimycobacterial drug concentrations have been observed in tuberculosis (TB) patients under treatment. The lactulose/mannitol urinary excretion test (L/M), normally used to measure intestinal permeability, may be useful to assess drug absorption. The objective of this research was to study intestinal absorptive function and bioavailability of rifampin and isoniazid in TB patients. A cross sectional study was done with 41 patients and 28 healthy controls, using the L/M test. The bioavailabilities of rifampin (R) and isoniazid (H) were evaluated in 18 patients receiving full doses. Urinary excretion of mannitol and lactulose, measured by HPLC, was significantly lower in TB patients. The serum concentrations of the drugs were below the expected range for R (8-24 mcg/mL) or H (3-6 mcg/mL) in 16/18 patients. Analyzing the drugs individually, 12/18 patients had low serum concentrations of R, 13/18 for H and 8/18 for both drugs. We suggest that there is a decrease in the functional absorptive area of the intestine in TB patients, which would explain the reduced serum concentrations of antituberculosis drugs. There is a need for new approaches to improve drug bioavailability in TB patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17420908     DOI: 10.1590/s1413-86702006000600003

Source DB:  PubMed          Journal:  Braz J Infect Dis        ISSN: 1413-8670            Impact factor:   1.949


  19 in total

1.  Malabsorption of antimycobacterial drugs as a cause of treatment failure in tuberculosis.

Authors:  João Bento; Raquel Duarte; Maria Céu Brito; Sónia Leite; Maria Rosário Lobato; Maria do Carmo Caldeira; Aurora Carvalho
Journal:  BMJ Case Rep       Date:  2010-09-29

2.  Pharmacokinetics of First-Line Drugs Among Children With Tuberculosis in Rural Tanzania.

Authors:  Museveni Justine; Anita Yeconia; Ingi Nicodemu; Domitila Augustino; Jean Gratz; Estomih Mduma; Scott K Heysell; Sokoine Kivuyo; Sayoki Mfinanga; Charles A Peloquin; Theodore Zagurski; Gibson S Kibiki; Blandina Mmbaga; Eric R Houpt; Tania A Thomas
Journal:  J Pediatric Infect Dis Soc       Date:  2020-02-28       Impact factor: 3.164

3.  Population pharmacokinetics of bedaquiline (TMC207), a novel antituberculosis drug.

Authors:  Sarah C McLeay; Peter Vis; Rolf P G van Heeswijk; Bruce Green
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

4.  Clinical Pharmacokinetics of Rifampin in Patients with Tuberculosis and Type 2 Diabetes Mellitus: Association with Biochemical and Immunological Parameters.

Authors:  S E Medellín-Garibay; N Cortez-Espinosa; R C Milán-Segovia; M Magaña-Aquino; J M Vargas-Morales; R González-Amaro; D P Portales-Pérez; S Romano-Moreno
Journal:  Antimicrob Agents Chemother       Date:  2015-10-05       Impact factor: 5.191

5.  Markers of gut dysfunction do not explain low rifampicin bioavailability in HIV-associated TB.

Authors:  Christopher Vinnard; Shruthi Ravimohan; Neo Tamuhla; Jotam Pasipanodya; Shashikant Srivastava; Chawangwa Modongo; Nicola M Zetola; Drew Weissman; Tawanda Gumbo; Gregory P Bisson
Journal:  J Antimicrob Chemother       Date:  2017-07-01       Impact factor: 5.790

6.  Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.

Authors:  S Thee; J A Seddon; P R Donald; H I Seifart; C J Werely; A C Hesseling; B Rosenkranz; S Roll; K Magdorf; H S Schaaf
Journal:  Antimicrob Agents Chemother       Date:  2011-10-03       Impact factor: 5.191

7.  Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations.

Authors:  Marc Weiner; Charles Peloquin; William Burman; Chi-Cheng Luo; Melissa Engle; Thomas J Prihoda; William R Mac Kenzie; Erin Bliven-Sizemore; John L Johnson; Andrew Vernon
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

8.  High early mortality in patients with chronic acquired immunodeficiency syndrome diarrhea initiating antiretroviral therapy in Haiti: a case-control study.

Authors:  Rebecca A Dillingham; Relana Pinkerton; Paul Leger; Patrice Severe; Richard L Guerrant; J William Pape; Daniel W Fitzgerald
Journal:  Am J Trop Med Hyg       Date:  2009-06       Impact factor: 2.345

9.  Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV.

Authors:  Kidola Jeremiah; Paolo Denti; Emmanuel Chigutsa; Daniel Faurholt-Jepsen; George PrayGod; Nyagosya Range; Sandra Castel; Lubbe Wiesner; Christian Munch Hagen; Michael Christiansen; John Changalucha; Helen McIlleron; Henrik Friis; Aase Bengaard Andersen
Journal:  Antimicrob Agents Chemother       Date:  2014-04-07       Impact factor: 5.191

Review 10.  Food for thought: addressing undernutrition to end tuberculosis.

Authors:  Pranay Sinha; Knut Lönnroth; Anurag Bhargava; Scott K Heysell; Sonali Sarkar; Padmini Salgame; William Rudgard; Delia Boccia; Daniel Van Aartsen; Natasha S Hochberg
Journal:  Lancet Infect Dis       Date:  2021-03-23       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.